LANCL2

Across TCGA pan-cancer cohorts, LANCL2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LANCL2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LANCL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LANCL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where LANCL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.659	0.416	<.001	102	view →
CCRCC	DFS	Median	III,IV	1.000	0.730	.001	26	view →
UCEC	OS	Median	III,IV	0.311	1.000	.001	24	view →
LSCC	DFS	Quartile	III,IV	0.878	0.324	.007	7	view →
COAD	DFS	Median	III,IV	0.897	1.000	.044	6	view →
LUAD	DFS	Median	All	0.848	0.947	.027	5	view →
HNSC	DFS	Median	All	0.985	0.919	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LANCL2–PDAC (OS)

Open the PDAC breakdown →